Convection-Enhanced Delivery of a Virus-Like Nanotherapeutic Agent with Dual-Modal Imaging for Besiegement and Eradication of Brain Tumors

Theranostics. 2019 Feb 28;9(6):1752-1763. doi: 10.7150/thno.30977. eCollection 2019.

Abstract

Convection-enhanced delivery (CED) is a promising technique for infusing a therapeutic agent directly into the brain, bypassing the blood-brain barrier (BBB) with a pressure gradient to increase drug concentration specifically around the brain tumor, thereby enhancing tumor inhibition and limiting the systemic toxicity of chemotherapeutic agents. Herein, we developed a dual-imaging monitored virus-like nanotherapeutic agent as an ideal CED infusate, which can be delivered to specifically besiege and eradicate brain tumors. Methods: We report one-pot fabrication of green-fluorescence virus-like particles (gVLPs) in Escherichia coli (E. coli) for epirubicin (EPI) loading, cell-penetrating peptide (CPP) modification, and 68Ga-DOTA labeling to form a positron emission tomography (PET)-fluorescence dual-imaging monitored virus-like nanotherapeutic agent (68Ga-DOTA labeled EPI@CPP-gVLPs) combined with CED for brain tumor therapy and image tracking. The drug delivery, cytotoxicity, cell uptake, biodistribution, PET-fluorescence imaging and anti-tumor efficacy of the 68Ga-DOTA labeled EPI@CPP-gVLPs were investigated in vitro and in vivo by using U87-MG glioma cell line and U87-MG tumor model. Results: The 68Ga-DOTA-labeled EPI@CPP-gVLPs showed excellent serum stability as an ideal CED infusate (30-40 nm in size), and can be disassembled through proteolytic degradation of the coat protein shell to enable drug release and clearance to minimize long-term accumulation. The present results indicated that 68Ga-DOTA-labeled EPI@CPP-gVLPs can provide a sufficiently high drug payload (39.2 wt% for EPI) and excellent detectability through fluorescence and PET imaging to accurately represent drug distribution during CED infusion. In vivo delivery of the 68Ga-DOTA-labeled EPI@CPP-gVLPs through CED demonstrated that the median survival was prolonged to over 50 days when the mice received two administrations (once per week) compared with the control group (median survival: 26 days). Conclusion: The results clearly indicated that a combination of 68Ga-DOTA-labeled EPI@CPP-gVLPs and CED can serve as a flexible and powerful synergistic treatment in brain tumors without evidence of systemic toxicity.

Keywords: brain tumor; convection-enhanced delivery (CED); dual-modal imaging; nanomedicine; virus-like particles (VLPs).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Brain Neoplasms / diagnostic imaging*
  • Brain Neoplasms / drug therapy*
  • Cell Line, Tumor
  • Cell-Penetrating Peptides / administration & dosage
  • Disease Models, Animal
  • Drug Carriers / administration & dosage*
  • Drug Carriers / pharmacokinetics
  • Epirubicin / administration & dosage
  • Humans
  • Mice, Nude
  • Optical Imaging
  • Organometallic Compounds / administration & dosage
  • Positron-Emission Tomography
  • Staining and Labeling / methods
  • Virosomes / administration & dosage*
  • Virosomes / pharmacokinetics

Substances

  • Antineoplastic Agents
  • Cell-Penetrating Peptides
  • Drug Carriers
  • Organometallic Compounds
  • Virosomes
  • Epirubicin
  • gallium Ga 68 dotatate